POPULARITY
2 episodes with tuberculosis tb
2 episodes with tuberculosis tb
2 episodes with tuberculosis tb
In a new book, author John Green traces how the disease has impacted culture, geography, and even fashion over the centuries.Tuberculosis (TB) has had an incredibly large impact on human history. One staggering statistic? It's been estimated that by the start of the 1800s, the disease had killed one in seven people who had ever lived. Because of this, tuberculosis affected human culture, geography, and fashion—and even killed off some of literature and media's most famous heroines.While TB incidence has gone down tremendously in the United States, it remains a massive issue in low-resource nations. About 1.25 million people die of TB each year, making it still the deadliest infectious disease in the world.Author John Green explores humankind's relationship with TB in the new book Everything is Tuberculosis: The History and Persistence of Our Deadliest Infection. Green speaks with Host Flora Lichtman about how TB's path reflects our society and culture. He joins us from Indianapolis, Indiana.Transcript for this segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
Host: Darryl S. Chutka, M.D. Guest: James T. Gaensbauer, M.D., M.S. Each year, we recognize World TB Day on March 24. This annual event commemorates the date in 1882 when Dr. Robert Koch announced his discovery of Mycobacterium tuberculosis, the bacillus that causes tuberculosis (TB). World TB Day is a day to educate the public about the impact of TB around the world. The CDC, along with our partners and colleagues around the world, share successes in TB prevention and control and raise awareness of the challenges that hinder our progress toward the elimination of this devastating disease. Tuberculosis continues to be a global health concern. Despite being preventable and very treatable, this disease continues to cause suffering and death. It accounted for an estimated one and a quarter million deaths worldwide in 2023. In the United States, cases have been increasing over the past several years, and this is also true in children, especially in those under the age of 5 years. What are the common risk factors for tuberculosis in children? Is the disease different in children compared to adults? What should we, as a primary care provider do when we suspect tuberculosis in a young patient? These are some of the questions I'll be asking my guest for this podcast, James T. Gaensbauer, M.D., M.S., a pediatric infectious disease specialist at the Mayo Clinic as we discuss “Tuberculosis in Children”. Connect with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development
In this podcast, Dr Andy Purbrick, Wessex LMCs Joint CEO is joined by David Thomas, TB Consultant Nurse from University Hospital Dorset. They discuss important aspects of Tuberculosis (TB), particularly focusing on the rise in TB cases, screening, risk factor groups and common signs and symptoms associated with the disease.
Tune in as Dr Sayontonee Ghosh gives an overview of TB including: Transmission Diagnosis Screening Symptoms Treatment options
This week's episode we will discuss the resurgence of TB/ Tuberculosis. TB is a treatable and curable disease. Active, drug-susceptible TB disease is treated with a standard 6-month course of 4 antimicrobial drugs that are provided with information and support to the patient by a health worker or trained volunteer. Without such support, treatment adherence is more difficult. Since 2000, an estimated 66 million lives were saved through TB diagnosis and treatment. (credits: WHO) A total of 1.5 million people died from TB in 2020 (including 214 000 people with HIV). Worldwide, TB is the 13th leading cause of death and the second leading infectious killer after COVID-19 (above HIV/AIDS). In 2020, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. 5.6 million men, 3.3 million women and 1.1 million children. TB is present in all countries and age groups. But TB is curable and preventable. In 2020, 1.1 million children fell ill with TB globally. Child and adolescent TB is often overlooked by health providers and can be difficult to diagnose and treat. In 2020, the 30 high TB burden countries accounted for 86% of new TB cases. Eight countries account for two thirds of the total, with India leading the count, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa. Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat. Only about one in three people with drug resistant TB accessed treatment in 2020. Globally, TB incidence is falling at about 2% per year and between 2015 and 2020 the cumulative reduction was 11%. This was over half way to the End TB Strategy milestone of 20% reduction between 2015 and 2020. An estimated 66 million lives were saved through TB diagnosis and treatment between 2000 and 2020. Globally, close to one in two TB-affected households face costs higher than 20% of their household income, according to latest national TB patient cost survey data. The world did not reach the milestone of 0% TB patients and their households facing catastrophic costs as a result of TB disease by 2020. By 2022, US$ 13 billion is needed annually for TB prevention, diagnosis, treatment and care to achieve the global target agreed at the UN high level-meeting on TB in 2018. Funding in low- and middle-income countries (LMICs) that account for 98% of reported TB cases falls far short of what is needed. Spending in 2020 amounted to US$ 5.3 billion less than half (41%) of the global target. There was an 8.7% decline in spending between 2019 and 2020 (from US$ 5.8 billion to US$ 5.3 billion), with TB funding in 2020 back to the level of 2016. Ending the TB epidemic by 2030 is among the health targets of the United Nations Sustainable Development Goals (SDGs). Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. Tuberculosis is curable and preventable. TB is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. About one-quarter of the world's population has a TB infection, which means people have been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit it. People infected with TB bacteria have a 5–10% lifetime risk of falling ill with TB. Those with compromised immune systems, such as people living with HIV, malnutrition or diabetes, or people who use tobacco, have a higher risk of falling ill. When a person develops active TB disease, the symptoms (such as cough, fever, night sweats, or weight loss) may be mild for many months. This can lead to delays in seeking care, and results in transmission of the bacteria to others. People with active TB can infect 5–15 other people through close contact over the course of a year. Without proper treatment, 45% of HIV-negative people with TB on average and nearly all HIV-positive people with TB will die. Who is most at risk? Tuberculosis mostly affects adults in their most productive years. However, all age groups are at risk. Over 95% of cases and deaths are in developing countries. People who are infected with HIV are 18 times more likely to develop active TB (see TB and HIV section below). The risk of active TB is also greater in persons suffering from other conditions that impair the immune system. People with undernutrition are 3 times more at risk. Globally in 2020, there were 1.9 million new TB cases that were attributable to undernutrition. Alcohol use disorder and tobacco smoking increase the risk of TB disease by a factor of 3.3 and 1.6, respectively. In 2020, 0.74 million new TB cases worldwide were attributable to alcohol use disorder and 0.73 million were attributable to smoking. Global impact of TB TB occurs in every part of the world. In 2020, the largest number of new TB cases occurred in the WHO South-East Asian Region, with 43% of new cases, followed by the WHO African Region, with 25% of new cases and the WHO Western Pacific with 18%. In 2020, 86% of new TB cases occurred in the 30 high TB burden countries. Eight countries accounted for two thirds of the new TB cases: India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa. Symptoms and diagnosis Common symptoms of active lung TB are cough with sputum and blood at times, chest pains, weakness, weight loss, fever and night sweats. WHO recommends the use of rapid molecular diagnostic tests as the initial diagnostic test in all persons with signs and symptoms of TB as they have high diagnostic accuracy and will lead to major improvements in the early detection of TB and drug-resistant TB. Rapid tests recommended by WHO are the Xpert MTB/RIF Ultra and Truenat assays. Diagnosing multidrug-resistant and other resistant forms of TB (see Multidrug-resistant TB section below) as well as HIV-associated TB can be complex and expensive. Tuberculosis is particularly difficult to diagnose in children.
Listen to the SBS Sinhala discussion on Things people should know about Tuberculosis (TB), which has officially surpassed COVID-19 to become the number one infectious disease killer globally - Tuberculosis (TB) හෙවත් ක්ෂය රෝගය, මේ වනවිට නිල වශයෙන් COVID-19 අභිබවා ගොස් ඇති බවට ලෝක සෞඛ්ය සංවිධානයේ ක්ෂය රෝගය පිළිබඳ නව වාර්තාවක් සඳහන් කරයි. එමෙන්ම 2023 වසරේදී දළ වශයෙන් මිලියන 8.2 ක ජනතාවකට අලුතින් ක්ෂය රෝගයෙන් වැලඳී තිබෙන බවත් ලෝක සෞඛ්ය සංවිධානය පෙන්වා දෙයි. මේ හේතුවෙන් Tuberculosis (TB) හෙවත් ක්ෂය රෝගය වැළඳුනු පිරිස සහ අවට සිටින පිරිස දැන සිටිය යුතු කරුණු සම්බන්ධයන් වන සාකච්චාවට සවන්දෙන්න
Tuberculosis (TB) was historically called "consumption" due to the dramatic weight loss and wasting away experienced by patients. The modern name "tuberculosis" was first published by J. L. Schönlein in 1832. Today, between 3% and 5% of the U.S. population are estimated to be living with latent TB infection. Contrast that with the worldwide statistics which state that nearly one fourth of the world population has TB infection. In some countries in sub-Saharan Africa and Asia, the annual incidence is several hundred per 100,000 population. In the US, the annual incidence is
Nandita Venkatesan, a Tuberculosis (TB) survivor and advocate, shares her journey of becoming a TB survivor and the challenges she faced in diagnosing, treating, and recovering from the disease. She discusses the stigma and misconceptions associated with TB and the need for greater awareness and understanding. Nandita also highlights her involvement in a lawsuit against Johnson & Johnson to improve access to TB treatment. The outcome of the lawsuit resulted in reduced prices for TB medications, demonstrating the power of advocacy efforts. She emphasizes the importance of improving access to shorter regimens, developing a new TB vaccine, and empowering patients with knowledge and information.Connect with Nandita on XTo support us, consider becoming a paid subscriber on Patreon or making a one-time donation via PayPal.Follow us on X (@unfiltered_gh), LinkedIn, Instagram, and TikTok.
The fight against the spread of Tuberculosis (TB) has been thrust back into the spotlight following a march by more than 600 Gauteng-based TB activists affiliated with the NPO, Rural Health Advocacy Project. The group has called for better co-ordination and greater political priority if government aims to eradicate TB by the year 2030. The march comes a just days after the Bill & Melinda Gates Medical Research Institute launched Phase 3 of a clinical trial to assess the efficacy of a TB vaccine which could potentially help prevent pulmonary TB in adolescents and adults. Sakina Kamwendo spoke to national principal investigator for the experimental vaccine called M72/AS01E (M72 for short)in South Africa, Dr Lee Fairlie.
HOUR 1Barbie movie soars in sales and weekend launch attendance / (MB) https://www.morningbrew.com/daily/stories/2023/07/23/barbenheimer-was-the-real-deal?Gaermany's Bettina Dorfmann, who set the Guinness World Record for owning Barbies / (MB) https://www.morningbrew.com/daily/stories/2023/07/23/barbenheimer-was-the-real-deal?Tom overviews the top 10 deadliest deadliest diseases in human history: 'Black Death (Bubonic Plague); Smallpox; Influenza Pandemics; HIV/AIDS: Malaria; Tuberculosis (TB); Cholera; Typhus; Measles; COVID-19Mosquito bites - what to know / (CBS News) https://www.cbsnews.com/video/dr-celine-gounder-on-mosquito-borne-diseases-and-climate-change/Tom talks about "The Thinker" which is the bronze sculpture by French sculptor Auguste RodinWhat happens to our bodies in extreme temperatures? / (NPR) https://www.npr.org/sections/health-shots/2023/07/23/1189506023/heres-what-happens-to-the-body-in-extreme-temperatures-and-how-heat-becomes-deadRecord hot temp in history is Death Valley / (SF Gate) https://www.sfgate.com/bayarea/article/what-is-hottest-temperature-in-death-valley-18254957.php"The Coming Collapse of China" author Gordon Chang breaks down China's finances on FOX News 'Making Money' / (FOX News) https://www.foxbusiness.com/video/6331498206112Tom discusses biggest economies on the globe and the largest citiesHOUR 2Alaska lawmaker send letter to Alaska's Attorney General re medical privacy and constitutional concerns / (ANS) https://www.alaskasnewssource.com/2023/07/21/alaska-lawmakers-pen-letter-attorney-general-over-medical-privacy-concerns/“NBC Nightly News” will broadcast live from Anchorage on Monday, with anchor Lester Holt hosting a special edition of the newscast focusing on the Alaskan NORAD (North American Aerospace Defense Command) Region / (ADN) https://www.adn.com/alaska-news/anchorage/2023/07/22/nbc-nightly-news-will-broadcast-live-from-anchorage-on-monday/The bodies of four occupants of a helicopter that crashed Thursday on the North Slope were recovered early Sunday morning, according to an Alaska State Troopers dispatch / (ADN) The bodies of four occupants of a helicopter that crashed Thursday on the North Slope were recovered early Sunday morning, according to an Alaska State Troopers dispatch.Tom talks about causes for aviation disasters Ambassador Francis Rooney on the presidential race
In this episode, we discuss technology's impactful role in making services accessible, specifically in the treatment of Tuberculosis (TB). Listen as Chris Buri, a TB survivor and patient advocate, shares his experience with TB treatment and the importance of patient support and advocacy in TB care. You'll also hear about his personal journey of resilience and advocacy, the challenges and opportunities presented by TB treatment, and the potential of technology such as VDOT (Video Directly Observed Therapy) to improve patient outcomes. This is a great listen for those wanting to learn more about the impact of TB on patients and their families, the need for person-centered care, and the important call to action for more research and funding in TB treatment and advocacy. Topics discussed: An introduction to Chris Buri, a TB survivor and patient advocate Chris's experience with TB treatment, including challenges with medication side effects and treatment adherence The importance of patient support and advocacy in TB treatment The role of support groups in providing emotional and practical support to TB patients The impact of TB on patients and their families, including social stigma and financial burden The need for patient-centered care in TB treatment, with a focus on patient empowerment and engagement The potential of technology to improve TB treatment adherence and patient outcomes The challenges and opportunities presented by the COVID-19 pandemic in TB treatment The need for more research and funding in TB treatment and advocacy Chris's call to action for healthcare providers, policymakers, and the public to prioritize TB treatment and support Related Resources SureAdhere: https://www.sureadhere.com CDC (Centers for Disease Control and Prevention): https://www.cdc.gov Colorado Department of Public Health: https://cdphe.colorado.gov Denver Health:https://www.phidenverhealth.org We are TB: https://www.wearetb.com Sign up to our newsletter, and stay informed of Dimagi's work :https://sites.dimagi.com/newsletter-sign-up We are on social media - follow us for the latest from Dimagi: LinkedIn: https://www.linkedin.com/company/dimagi Twitter:https://twitter.com/dimagi/Facebook:https://www.facebook.com/dimagi.inc/Youtube:https://www.youtube.com/channel/UCt8JcRhWywkVJRR_YWv4OhA If you enjoy this show, please leave us a 5-Star Review and share your favorite episodes with friends. Hosts: Jonathan Jackson: https://www.linkedin.com/in/jonathanljackson/ Amie Vaccaro: https://www.linkedin.com/in/amievaccaro/
Consumption. The White Plague. Scrofula. Tuberculosis (TB) has been known by so many names over the ages, and those names reflect just how long it's been around and just how misunderstood it's been. It's killed kings and generals, playwrights, and poets.TB still sickens 10 million people every year and kills 1.5 million – even though it's easily prevented and can be treated. It's unusual because it needs to be treated even if the person infected has no symptoms at all.And even though it's an ancient disease, TB keeps evolving into new and ever more unpleasant forms. Now, multi-drug-resistant (MDR) TB infects half a million people around the world each year, according to the World Health Organization. A third of these MDR TB infections go undetected, and that means there are tens of millions of people who do not get the treatment they need and who can go on to infect others.Dr. Jeffrey Tornheim has been studying ways to test people to quickly and easily tell if they've got a drug-resistant form of TB infection and need special medications to treat it right away. Quick information can help stop the spread of these dangerous forms of the infection and can ensure that patients and health professionals don't waste time, money, and medicine with the wrong treatments. In this episode of One World One Health, Dr. Tornheim, Assistant Professor of Medicine and Assistant Professor of Pediatrics at the Johns Hopkins University School of Medicine, as well as at the Johns Hopkins Bloomberg School of Public Health, chats with host Maggie Fox about why TB is so hard to fight and how genomics can make that fight a little easier.
Tuberculosis (TB) one of the most deadly and enduring diseases, has been thriving in a world that has been sidetracked by the COVID-19 pandemic. Case numbers and deaths have climbed to new highs and previous hopes for a T-B-free world by 2030 now seem unlikely. Experts reveal tuberculosis will remain a global epidemic for many decades, whereas extensive efforts and resources are needed to mitigate its impact.
The Indian Patents Office on Thursday rejected an application of global pharma major Johnson and Johnson seeking an extension of its patent on anti-Tuberculosis (TB) drug Bedaquiline beyond July 2023, when it is set to expire. Why is this significant? Will it help TB patients in India? The Hindu businessline's Senior Deputy Editor G Naga Sridhar explains in this episode of News Explained. Tune in to know more. --- Send in a voice message: https://podcasters.spotify.com/pod/show/business-line/message
DIA ESPECIAL l Día Mundial de Lucha Contra la Tuberculosis Cada año, el 24 de marzo, se conmemora el Día Mundial de la Tuberculosis (TB) para concientizar a la población sobre las devastadoras consecuencias sanitarias, sociales y económicas de la TB, y para intensificar los esfuerzos para acabar con esta epidemia mundial. La fecha conmemora el día en el Dr. Robert Koch anunció que había descubierto la bacteria que causa la tuberculosis en 1882, lo que abrió el camino hacia el diagnóstico y la cura de esta enfermedad. #tuberculosis #tb #lucha #salud #arribacorazones
Tune into the Public Health Insight Podcast as we explore some more fascinating and thought-provoking topics that are sure to spark your interest. In this episode, we discuss:◼️ Guinea worm - a parasitic disease that has plagued humans for centuries, and what it will take to get to zero cases globally.◼️ Tuberculosis (TB) - a disease that has once again become the deadliest in Africa. What has gone wrong, why progress has stalled, and what needs to be done to get back on track? ◼️ The link between HBO's hit series “The Last of US,” the rise of drug-resistant fungal infections in the real world; and the need for vaccines in the face of scientific and economic challenges.Articles Covered◼️ Guinea worm: A nasty parasite is nearly eradicated, but the push for zero cases will require patience (The Conversation)◼️ TB is once again the deadliest disease in Africa - what went wrong (The Conversation)◼️ Why don't we have vaccines for fungal infections? (Vox)Podcast Hosts◼️ Gordon Thane, BMSc, MPH, PMP®◼️ Leshawn Benedict, MPH, MSc, PMP®Subscribe to the NewsletterSubscribe to the newsletter so you don't miss out on the latest podcast episodes, live events, jobs, learning opportunities, and other engaging professional development content here.Leave Us A Five Star RatingIf you enjoy our podcasts, be sure to subscribe and leave us a rating on Apple Podcast or Spotify, and spread the word to your friends to help us get discovered by more people.
In a special 3-part season premiere, Halteres Presents is spotlighting tuberculosis diagnostics worldwide, and where things stand in the field today. In Part Three, Rich Thayer and Mickey Urdea are interviewing Dr. Shibu Vijayan, the Medical Director for Global Health Practice at Qure.ai, a healthtech company that uses artificial intelligence assistance for medical imaging diagnostics. Dr. Vijayan is a senior clinician in Community and Public Health Services with over 25 years of experience in developing, monitoring, and evaluating public health projects, including developing healthcare-related proposals in both private and not-for-profit organizations. He is also an accredited International general Tuberculosis (TB) expert by the TB team hosted by WHO and Stop TB Partnership. Prior to Qure.ai, Dr. Vijayan was at PATH and has also worked with the WHO as Technical Consultant for the TB Control Program in India and was associated with Medicines Sans Frontiers (MSF, Netherlands) as a field Epidemiologist in Ethiopia.
With COVID infections and deaths on the decline worldwide, many researchers are turning their attention back to a familiar foe. Tuberculosis (TB) was the number one infectious disease killer before the emergence of COVID-19, and it is number one again today. Although most Americans are not at risk of contracting TB, it continues to be a danger worldwide. TGen researchers are trying to find better diagnostics for this very stubborn bacterial infection, and combat antibiotic resistance so that doctors everywhere can better treat this ancient illness. TGen North research scientist Megan Folkerts joins TGen Talks to discuss TB's history, Egyptian mummies, TGen North's efforts to design better diagnostics, learning how antibiotic resistance stunts treatment, and improved ways to overcome its effects on new or current therapies. All this and more on TGen Talks.
Dr Jo Peel, Sexual Health Physician, unpacks the stigma assocaited with sexually transmitted infections (STIs); Associate Professor Suman Majumdar, Deputy Program Director (Health Security and Know-C19), Co-head of the Tuberculosis Elimination and Implementation Science Working Group and a Principal Research Fellow at the Burnet Institute, canvasses the symptoms, causes, and treatment of Tuberculosis (TB); and the team explore the impact of being phubbed, and discuss the achievements of Chinese Pharmaceutical Chemist and Malariologist Tu Youyou. With presenters Nurse Epipen, Miss Understanding, and Panel Beater. Website: https://www.rrr.org.au/explore/programs/radiotherapyFacebook: https://www.facebook.com/RadiotherapyOnTripleR/Twitter: https://twitter.com/_radiotherapy_Instagram: https://instagram.com/radiotherapy_tripler
CORDIScovery – unearthing the hottest topics in EU science, research and innovation
Tuberculosis (TB) is preventable and curable, and yet 9 900 000 people fell ill with the disease in 2020 and 1.5 million died. This episode is looking at what the EU is doing to curb the spread and improve our understanding of the nature of the illness. This episode of CORDIScovery hears from three researchers who have all been at the forefront of controlling the spread of the disease. New, cheap and non-invasive tests; drilling down into the pathogen's genome to get a clearer understanding of how it spreads; work done at a molecular level to establish how the bacteria switch from latent to active infection – all vital if we are to get a handle on controlling and preventing outbreaks. Hossam Haick is dean at the Israel Institute of Technology, the Technion. His work developing A-Patch, a skin patch test that is effective, cheap and can transmit infection data to healthcare workers remotely, was supported by both the EU and the Bill and Melinda Gates Foundation. Teresa Cortes is based at the Institute of Biomedicine of Valencia, part of the Spanish National Research Council. She is interested in understanding how the bacteria that cause TB in humans infect, survive, cause disease and develop antibiotic resistance. Teresa was involved in the MtbTransReg project. Iñaki Comas, who explains the findings of his project TB-ACCELERATE, is also a researcher at the Institute of Biomedicine of Valencia. He is working on unravelling the intricacy of TB's genomics to understand the evolution and epidemiology of infectious diseases. His lab is particularly focused on TB, but also works on other diseases, like COVID-19.
Tuberculosis (TB) was once one of the most common and deadliest infectious diseases in the world. Even to this day, it still impacts millions of people, with over 10 million new cases, and approximately 1.3 million deaths each year. Dr. Gonzalo Alvarez is a Respirologist and Scientist at The Ottawa Hospital. Much of his work is focused on TB research among Canadian Inuit and in new Canadians. He is currently leading the Taima TB program of research. Taima (means stop in Inuktitut) TB is a group of research projects aimed at helping Inuit in Canada stop the transmission of TB in their communities. In this episode, he discusses some of his most recent research in TB, what is known about the illness, and why it impacts certain populations. On Call: The Ottawa Hospital Podcast features stories of care, innovation and compassion in health care, all happening right here at The Ottawa Hospital.
Many people think that Tuberculosis (TB) is a disease safely tucked away in human history, but that's not the case. Not only does it still lurk in communities around the globe, but it also claims over a million lives each year. Join us as we discuss this preventable and treatable disease with our guest Maureen Murphy-Weiss, BSN, RN, as she walks us through TB's lengthy history, common symptoms, and current treatments. Additionally, the episode tackles the effects of the COVID-19 pandemic on TB from both the patient's and the infection preventionist's perspective. Hosted by: Silvia Quevedo, CAE About our Guest: Maureen Murphy-Weiss, BSN, RN, Director, Ben Franklin TB Program, Columbus Public Health Maureen is the Tuberculosis Program Director at Columbus Public Health in Columbus, Ohio. She is a registered nurse in the state of Ohio and received her Associate Degree in Nursing from Kettering College and Bachelor's Degree in nursing from Capital University in 2006. In 1997, Maureen started in local public health and later moved to the state health department. While working at the Ohio Department of Health, from 2003 to 2016, she filled a variety of leadership positions, including state TB Controller, and manager for the viral hepatitis and healthcare-associated infection programs. She left the state in late 2016, after accepting a position at Columbus Public Health. In March 2020, Maureen was named operations chief for Columbus Public Health's pandemic incident command structure. Her experience with respiratory isolation, contact tracing, and health care service delivery in community settings informed many decisions in the agency's COVID-19 response. Maureen is the immediate past president of the National TB Nurse Coalition, and currently serves on national workgroups for issues pertaining to tuberculosis prevention and COVID-19.
Grandfather was coughing for two months and losing weight.
On this week's episode we are discussing Tuberculosis, or TB. Currently the infection has a rate of infection that is only 2.2 per 100,000 persons. TB is more common in countries where many people live in absolute poverty because people are more likely to: live and work in poorly ventilated and overcrowded conditions, which provide ideal conditions for TB bacteria to spread suffer from malnutrition and disease – particularly HIV – which reduces resistance to TB have limited access to healthcare – and just one person with untreated infectious TB can pass the illness on to 10-15 people annually. Other TB Facts: A total of 1.5 million people died from TB in 2020 (including 214 000 people with HIV). Worldwide, TB is the 13th leading cause of death and the second leading infectious killer after COVID-19 (above HIV/AIDS). In 2020, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. 5.6 million men, 3.3 million women and 1.1 million children. TB is present in all countries and age groups. But TB is curable and preventable. In 2020, 1.1 million children fell ill with TB globally. Child and adolescent TB is often overlooked by health providers and can be difficult to diagnose and treat. In 2020, the 30 high TB burden countries accounted for 86% of new TB cases. Eight countries account for two thirds of the total, with India leading the count, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa. Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat. Only about one in three people with drug resistant TB accessed treatment in 2020. Globally, TB incidence is falling at about 2% per year and between 2015 and 2020 the cumulative reduction was 11%. This was over half way to the End TB Strategy milestone of 20% reduction between 2015 and 2020. An estimated 66 million lives were saved through TB diagnosis and treatment between 2000 and 2020. Globally, close to one in two TB-affected households face costs higher than 20% of their household income, according to latest national TB patient cost survey data. The world did not reach the milestone of 0% TB patients and their households facing catastrophic costs as a result of TB disease by 2020. By 2022, US$ 13 billion is needed annually for TB prevention, diagnosis, treatment and care to achieve the global target agreed at the UN high level-meeting on TB in 2018. Funding in low- and middle-income countries (LMICs) that account for 98% of reported TB cases falls far short of what is needed. Spending in 2020 amounted to US$ 5.3 billion less than half (41%) of the global target. There was an 8.7% decline in spending between 2019 and 2020 (from US$ 5.8 billion to US$ 5.3 billion), with TB funding in 2020 back to the level of 2016. Ending the TB epidemic by 2030 is among the health targets of the United Nations Sustainable Development Goals (SDGs). Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. Tuberculosis is curable and preventable. TB is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. About one-quarter of the world's population has a TB infection, which means people have been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit it. People infected with TB bacteria have a 5–10% lifetime risk of falling ill with TB. Those with compromised immune systems, such as people living with HIV, malnutrition or diabetes, or people who use tobacco, have a higher risk of falling ill. When a person develops active TB disease, the symptoms (such as cough, fever, night sweats, or weight loss) may be mild for many months. This can lead to delays in seeking care, and results in transmission of the bacteria to others. People with active TB can infect 5–15 other people through close contact over the course of a year. Without proper treatment, 45% of HIV-negative people with TB on average and nearly all HIV-positive people with TB will die. Who is most at risk? Tuberculosis mostly affects adults in their most productive years. However, all age groups are at risk. Over 95% of cases and deaths are in developing countries. People who are infected with HIV are 18 times more likely to develop active TB (see TB and HIV section below). The risk of active TB is also greater in persons suffering from other conditions that impair the immune system. People with undernutrition are 3 times more at risk. Globally in 2020, there were 1.9 million new TB cases that were attributable to undernutrition. Alcohol use disorder and tobacco smoking increase the risk of TB disease by a factor of 3.3 and 1.6, respectively. In 2020, 0.74 million new TB cases worldwide were attributable to alcohol use disorder and 0.73 million were attributable to smoking. Global impact of TB TB occurs in every part of the world. In 2020, the largest number of new TB cases occurred in the WHO South-East Asian Region, with 43% of new cases, followed by the WHO African Region, with 25% of new cases and the WHO Western Pacific with 18%. In 2020, 86% of new TB cases occurred in the 30 high TB burden countries. Eight countries accounted for two thirds of the new TB cases: India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa. Symptoms and diagnosis Common symptoms of active lung TB are cough with sputum and blood at times, chest pains, weakness, weight loss, fever and night sweats. WHO recommends the use of rapid molecular diagnostic tests as the initial diagnostic test in all persons with signs and symptoms of TB as they have high diagnostic accuracy and will lead to major improvements in the early detection of TB and drug-resistant TB. Rapid tests recommended by WHO are the Xpert MTB/RIF Ultra and Truenat assays. Diagnosing multidrug-resistant and other resistant forms of TB (see Multidrug-resistant TB section below) as well as HIV-associated TB can be complex and expensive. Tuberculosis is particularly difficult to diagnose in children. Treatment TB is a treatable and curable disease. Active, drug-susceptible TB disease is treated with a standard 6-month course of 4 antimicrobial drugs that are provided with information and support to the patient by a health worker or trained volunteer. Without such support, treatment adherence is more difficult. Since 2000, an estimated 66 million lives were saved through TB diagnosis and treatment. (credits: WHO)
There is an infectious disease affecting people all around the world and was responsible for more than 1 million deaths globally in 2020. If you had to guess, maybe you would think it was COVID-19. Think again, because it's a disease that was first discovered in the 1800s, called Tuberculosis (TB). In this episode of the Public Health Insight Podcast, we'll be speaking with two guests from Stop TB Canada about:The history of TB in Canada and the current burden of disease;How the TB programs at Toronto Public Health and the Northern Inter-Tribal Health Authority (NITHA) typically operate;The impact of COVID-19 on patients and services; andThe urgent need to prioritize programs targeted to the prevention, control, and elimination of this disease.Podcast GuestTina Campbell, BSN, RN Dr. Elizabeth Rea, MDPodcast HostsLeshawn Benedict, MPH, MSc, PMP®Gordon Thane, BMSc, MPH, PMP®References for Our DiscussionSTOP TB CanadaNorthern Inter-Tribal Health Authority (NITHA)Toronto Public HealthSubscribe to the NewsletterWhat if there was an easy way to receive timely information about public health and global health right to your inbox? Subscribe to the newsletter to stay in the loop about the latest news, live events, jobs, and professional development opportunities. Subscribe to ensure you don't miss out: https://thepublichealthinsight.com/subscribe/.Leave Us a RatingIf you enjoy our podcasts, be sure to subscribe and leave us a rating on Apple Podcast or Spotify, and spread the word to your friends to help us get discovered by more people.Teaching MaterialsIf you are an educator interested in using any of our podcast material in your teaching material, feel free to do so or reach out through at thepublichealthinsight@gmail.com. We'd also be happy to connect regarding any guest lecture opportunities. Learn more about our previous collaborations. Support the show (https://www.buymeacoffee.com/PHInsight)
Though Mycobacterium tuberculosis may have been existing for as long as 3 million years, Johann Schonlein coined the term "tuberculosis" in 1834.Tuberculosis (TB) was known in ancient Greece as "phthisis," in ancient Rome as "tabes," and in ancient Hebrew as "schachepheth." Due to the paleness of the sufferers, tuberculosis was dubbed "the white plague" in the 1700's. Even after Schonlein named it tuberculosis, TB was referred to as "consumption" in the 1800's. TB was also known as the "Captain of all these men of death" during this time.Firland Sanatorium, Seattle's municipal tuberculosis hospital, opened on the 2nd of May, 1911, to assist in combating the city's main cause of death at the time, tuberculosis. Firland was a 34-acre estate in the Richmond Highlands area, 12 miles north of Seattle's then-border (in 1995 this first Firland site became part of the newly incorporated City of Shoreline). The hospital remained there until 1947, when it was moved to a former Naval hospital (at 15th Avenue NE and 150th Street) and continued to treat tuberculosis patients until 1973. The railroad mogul Horace C. Henry, whose son Walter had died of tuberculosis, was a key founder of Firland Sanatorium.Listen now to learn more!Check out the podcast's Facebook page to stay up to date on the show:https://www.facebook.com/HistoryoftheevergreenstatepodcastA special thank you goes out to Al Hirsch for providing the music for the podcast, check him out on YouTube.Find merchandise for the podcast now available at:https://washington-history-by-jon-c.creator-spring.comIf you have any questions, episode ideas you'd like to see explored, or just have a general comment, please reach out at Historyoftheevergreenstatepod@gmail.comThank you for listening!
While McDonald's isn't self care, maybe Jersey Mikes is? Welp, it was for the Bewitches this week. Oops. We'll get there. Amy goes back to Victorian times and shares how consumption's (Tuberculosis -TB) symptoms of pale skin, rosy cheeks, and waif-like figures became some of the top female beauty standards of the time. She also STILL doesn't watch SNL, so Amy doesn't get Krista's reference to Weekend Update's spoof on Goop with a cameo from GP (Gwyneth Paltrow) herself. Meanwhile, as Krista rants about this “self-care” company's pseudo science practices, Amy not-so-secretly wants to work for Goop. Hit ‘er up GP! See full ep notes and resources here: https://www.bewitchedbanter.com/episodes
Researchers at the Council for Scientific and Industrial Research (CSIR) briefed the media on Friday on some of the organisation's research, development and innovation (RDI) efforts aimed at addressing the HIV/AIDS and Tuberculosis (TB) epidemics in South Africa. CSIR researcher Dr Advaita Singh shed light on an innovative plant-based, highly potent anti-HIV antibodies research initiative. “The CSIR's plant-based anti-HIV antibodies research is aimed at developing a cost-effective pre prophylaxis vaccine which will passively immunise against HIV/AIDS, pre and post exposure. This initiative was inspired by the desire to empower young girls and women to protect themselves against the virus as studies have indicated that women are theoretically, at higher risk of HIV acquisition,” said Singh. Working with the National Institute of Communicable Diseases (NICD), the CSIR is developing broadly neutralising antibodies against HIV-1, the most widespread human immunodeficiency virus, for the prevention and treatment of HIV/AIDS. CSIR scientists and their research partners were able to demonstrate the ability to engineer tobacco plants to produce unique glycosylation and rare sulfation post-translational modifications, a result that is not usually seen in plants. Glycosylation is a biochemical process during which a glycan – a large carbohydrate molecule – attaches to a protein, a lipid, or another organic molecule. The glycoengineered Nicotiana benthamiana (a relative of the tobacco plant) expressed two broadly neutralising antibodies named CAP256-VRC26 08 and CAP256-VRC26 09. These two antibodies were originally isolated by collaboration Aids research centre CAPRISA and the NICD from a South African HIV positive patient during a trial conducted by CAPRISA. The outcome showed that the antibodies from the CAP256 lineage were the most active, with high potency and broad specificity. “We still have a number of steps to get through, as the research process commonly requires, before this technology is available in the market, however, the CSIR and its partners intends on making it accessible to patients through an industry partner once it is ready,” added Singh. Another technology presented by the CSIR at the media briefing aims to provide rural areas with a diagnostic assay that will test for HIV and TB simultaneously using one device in the comfort of the patient's home. CSIR lab technician Kanyane Malatji provided insight into a multiplex HIV and TB point-of-care diagnostic test being developed for use in remote and rural areas. “The effective management of patients infected with HIV and TB is restricted by separate diagnoses. The situation is exacerbated in remote areas where patients must either travel long distances to reach a healthcare facility or wait a long time before obtaining their TB diagnostic results. Therefore, through our multiplex HIV and TB point-of-care diagnostic assay, we hope to mitigate these challenges with the objective of improving treatment outcomes for patients in rural areas,” said Malatji. The locally developed diagnostic test uses a solid surface that couples the HIV and TB antigens and makes use of a locally produced fluorescence detector. “The benefits of this technology are that it offers a cost-effective solution with a low turnaround time of approximately 2 hours. Additionally, no laboratory infrastructure is required, the device is easy to use and can be performed at point-of-care without highly trained personnel,” added Malatji. The CSIR's multiplex HIV and TB point-of-care diagnostic assay is funded by government and the plant-based anti-HIV antibodies research work is funded by the Department of Science and Innovation and the South African Medical Research Council.
In this episode, we spoke to Jonathan O'Halloran, Founder and CEO at QuantumDX, a molecular diagnostics technology company based in the North-East. We talked to Jonathan about his journey from academia to business, his travels around the world working on diagnostics for Tuberculosis (TB), and the challenges that come with quickly scaling production of a product in the face of huge demand.
To mark World TB Day, Katherine E. Bliss and J. Stephen Morrison speak with Adrian Thomas, TB expert and leader of global strategy at Johnson & Johnson Global Health. Every year, TB kills an estimated 1.4 million people and infects another 10 million people, with about 400,000 of those cases resistant to two or more drugs. Covid-19 has disrupted health systems and displaced funding and frontline staff away from TB, which models estimate will cause an additional million cases per year over the next five years. In this episode, we talk to Adrian about the grave impact the pandemic is having on global TB efforts, how to build local health security capacities that control TB and respond to future outbreaks, how international scientific partnerships speed up R&D and create platforms with broad applications, and the recent emergency use authorization by the FDA of J&J's Covid-19 vaccine. Adrian Thomas is Vice President for Strategy and External Affairs at Johnson & Johnson Global Health. The views expressed in the podcast are personal and not those of his employer.
Each year March 24 is observed as World Tuberculosis (TB) Day to raise public awareness about the devastating health, social and economic effects of TB. This day is also used to increase the efforts to end the global TB epidemic. World TB Day is one of the eleven official global public health campaigns marked by the World Health Organization (WHO) March 24 is selected in the remembrance of the same day in 1882 when Dr. Robert Koch announced that he had discovered the bacterium that causes TB. Compiled & Presented by : Abdul Credits, Image by oracast from Pixabay
In this week's episode of Podcast from Washington, NACCHO government affairs team members Ian Goldstein and Eli Briggs discuss the passage of the American Rescue Plan Act and the investments it makes in the public health response to the COVID-19 Pandemic and beyond. They also discuss the Centers for Disease Control and Prevention (CDC) investment announced this week to address COVID-19-related health disparities and health equity. Later in the program, Ian talks with Tuberculosis Control Officer at Seattle & King County Public Health Dr. Masa Narita as well as Country Director with the CDC Division of Global HIV/AIDS in Zambia Dr. Simon Agolory. Both guests discuss World TB day and how the COVID-19 pandemic has severely impacted TB prevention and control efforts both globally and domestically.
Tuberculosis (TB) is a bacterial infectious disease that affects millions of people globally every year. Despite being one of the oldest infectious diseases in humans, control of the epidemic through treatment and vaccination has remained out of reach. In today’s episode, we learned about what makes TB so difficult to control, from immunology to stigma. First, Dr. Jun Liu, a Professor in the Department of Molecular Genetics at University of Toronto, guides us through current knowledge on TB and discusses the difficulties and advances in developing TB vaccines. Next, Dr. Amrita Daftary, a Professor in the Department of Global Health at York University, explains the process of diagnosing and treating TB, and later highlights challenges that patients with TB may face while accessing care. Finally, Dr. Sarah Fortune, the Director of TB Research Program at Harvard T. H. Chan School of Public Health, helps us understand how TB drug resistance can arise, and why TB-HIV co-infection poses such a challenge. The figure against TB continues every day, by millions of patients, healthcare providers, and researchers alike. Join us as we learn about this forgotten pandemic. Dr. Jun Liu - profile Dr. Amrita Daftary - profile Dr. Sarah Fortune - profile What is DOTS? - report Paul Farmer on Partners in Health, Harvard-Haiti, and making the lives of the poor the fight of his life TB Personal Stories Vaccine Preventable Diseases
Tuberculosis (TB) is a bacterial infectious disease that affects millions of people globally every year. Despite being one of the oldest infectious diseases in humans, control of the epidemic through treatment and vaccination has remained out of reach. In today’s episode, we learned about what makes TB so difficult to control, from immunology to stigma. First, Dr. Jun Liu, a Professor in the Department of Molecular Genetics at University of Toronto, guides us through current knowledge on TB and discusses the difficulties and advances in developing TB vaccines. Next, Dr. Amrita Daftary, a Professor in the Department of Global Health at York University, explains the process of diagnosing and treating TB, and later highlights challenges that patients with TB may face while accessing care. Finally, Dr. Sarah Fortune, the Director of TB Research Program at Harvard T. H. Chan School of Public Health, helps us understand how TB drug resistance can arise, and why TB-HIV co-infection poses such a challenge. The figure against TB continues every day, by millions of patients, healthcare providers, and researchers alike. Join us as we learn about this forgotten pandemic. Dr. Jun Liu - profile Dr. Amrita Daftary - profile Dr. Sarah Fortune - profile What is DOTS? - report Paul Farmer on Partners in Health, Harvard-Haiti, and making the lives of the poor the fight of his life TB Personal Stories Vaccine Preventable Diseases
Molecular testing in Tuberculosis (TB) is broad and complex. Dr Andrew Burke and Dr Chris Coulter discuss the utility/ advantages of Ultra GeneExpert, different types of line probe assays and WGS/ NGS in the future. Dr Chris Coulter uses his expertise to explain these diagnostic tools for physicians, nurses, policy makers and public health professionals.Dr Chris Coulter is a Microbiologist, the Chair of TB Expert Advisory Group for Tuberculosis in QLD, and the Director of the Queensland Mycobacterium Reference Laboratory.
In the first episode of the podcast, Dr. Amy Gillgrass joins us to discuss her path through academia, raising a family while pursuing research, and what it takes to start and run a laboratory. Dr. Gillgrass received her PhD at McMaster University and joined the McMaster Immunology Research Centre as an assistant professor in 2018, where she began her research program studying Immunodeficiency Virus (HIV) and Tuberculosis (TB) co-infection. Make sure to follow us on Twitter @immunoNbeyond.
Doctors John and Guy consume themselves with a rich discussion of all things Tuberculosis. A conversation that spans the great "Lunger Migration" of the 19th century, New England Vampires, and Doc Holiday. You're Welcome.
On this week's The Sci-Files, your hosts Chelsie and Danny interview John Tison Williams. John is a PhD-candidate in the Department of Microbiology and Molecular Genetics through the College of Natural Sciences. John is in his 5th year and completing his dissertation, which focuses on understanding how small molecules inhibit the growth of Mycobacterium tuberculosis in Dr. Robert B. Abramovitch's lab. M. tuberculosis is the primary cause of Tuberculosis (TB), a respiratory infection and the number one cause of death due to a single infectious microbe in the world. TB is a chronic infection, and treatment requires four drugs to be taken daily for 6 months. However, inadequate treatment in some people, has led to the evolution of drug-resistant strains of M. tuberculosis, which are spreading person to person. Therefore, new drugs are needed that can successfully treat these resistant strains. The Abramovitch lab previously identified over one hundred and fifty compounds that inhibit M. tuberculosis growth. John's research revolves around understanding how these compounds prevent M. tuberculosis growth with the hope of developing these compounds into new antibiotics to treat these resistant strains. If you're interested in talking about your MSU research on the radio or nominating a student, please email Chelsie and Danny at scifiles@impact89fm.org. You can ask questions about future episodes here. Check The Sci-Files out on Twitter, Facebook, Instagram, and YouTube!
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.05.236711v1?rss=1 Authors: Tran, V. N.-N., Shams, A., Ascioglu, S., Martinecz, A., Liang, J., Clarelli, F., Mostowy, R., Cohen, T., Abel zur Wiesch, P. Abstract: Motivation: As antibiotic resistance creates a significant global health threat, we need not only to accelerate the development of novel antibiotics but also to develop better treatment strategies using existing drugs to improve their efficacy and prevent the selection of further resistance. We require new tools to rationally design dosing regimens to from data collected in early phases of antibiotic and dosing development. Mathematical models such as mechanistic pharmacodynamic drug-target binding explain mechanistic details of how the given drug concentration affects its targeted bacteria. However, there are no available tools in the literature that allows non-quantitative scientists to develop computational models to simulate antibiotic-target binding and its effects on bacteria. Results: In this work, we have devised an extension of a mechanistic binding-kinetic model to incorporate clinical drug concentration data. Based on the extended model, we develop a novel and interactive web-based tool that allows non-quantitative scientists to create and visualize their own computational models of bacterial antibiotic target-binding based on their considered drugs and bacteria. We also demonstrate how Rifampicin affects bacterial populations of Tuberculosis (TB) bacteria using our vCOMBAT tool. Availability: vCOMBAT online tool is publicly available at https://combat-bacteria.org/. Copy rights belong to original authors. Visit the link for more info
Aim & Sera continue their discussion of the many tragedies involved in Victorian clothing including the damage done by corsets, restrictive collars, flammable fabrics, fashion victims, and how the horrifying disease that is Tuberculosis (TB) plays into it all.Dead, My Dearest's theme is "Haunted" by Ross Bugden, and he's available on Twitter (@rossbugden) and Instagram (rossbugden).Follow Dead, My Dearest on Twitter (@deadmydearest), Instagram (deadmydearest), and Facebook (www.facebook.com/deadmydearest).
Tuberculosis (TB) remains one of the most prevalent infectious diseases in the world, with approximately 10 million people becoming sick and 1.5 million people dying every year from Mycobacterium tuberculosis infection. Dr. William Jacobs is a Professor at the Albert Einstein College of Medicine and member of the National Academy of Sciences who studies M. tuberculosis. TB is notoriously difficult to treat, due to the slow growth and persistence of the bacteria in the lungs, requiring extensive antibiotic treatment over a long period of time. Dr. Jacobs talks about the history of tuberculosis (“consumption”) in humans, how M. tuberculosis can hang out in the lungs for an entire lifetime, how slow growth is a bacterial strategy to avoid killing by antibiotics, how growth in armadillos is required to study the closely related M. leprae (causes leprosy), just how scary drug-resistant TB strains are, and how dirt from the Bronx Zoo was hiding a genetic tool that was a game-changer for the study of TB. The microCase for listeners to solve is about Ella Copta and Lana Jorgia, two internet vloggers who become ill after visiting an African shaman. Participants: Karl Klose, Ph.D. (UTSA) William Jacobs, Ph.D. (Albert Einstein College of Medicine) Janakiram Seshu, Ph.D. (UTSA) Mylea Echazarreta (UTSA) Abigail Blaschke (UTSA) Jacobi Brown (UTSA)
10/29/19 - Host Doug Stephan and Dr. Jack Stockwell, www.forbiddendoctor.com Phone: 866-867-5070 review the whole story behind the 60-year-old Chinese woman who just gave birth. Then a look at Tuberculosis (TB) and a new vaccine on the scene. In the olden days, TB patients were given 6 raw eggs a day. Dr. Jack provides simple ways to get your body moving, without joining a gym. Next, it's agreed that planning healthy meals for a family of 4 is a full-time job. Remember, big meals may be lacking in real nutrition. Plus, lots more tips and ideas for maintaining your good health.
Talk to a Dr. Berg Keto Consultant today and get the help you need on your journey (free consultation). Call 1-540-299-1557 with your questions about Keto, Intermittent Fasting, or the use of Dr. Berg products. Consultants are available Monday through Friday from 8:30 am to 9 pm EST. Saturday & Sunday 9 am to 5 pm EST. USA Only. Take Dr. Berg's Free Keto Mini-Course! Someone was recently wondering what would be good for TB (tuberculosis). In this video, I'm going to fill you in on a few essential things to know about TB. I also want to tell you about a vitamin that may act as the best remedy out there for you. Which vitamins for TB should I take? - The number one vitamin a person needs if they have TB is vitamin D3. Vitamin D3 may actually speed up recovery, lessen TB symptoms, and even put the person in remission. D3 controls the immune system. If you have a vitamin D deficiency, you're susceptible to getting an infection from either a virus or bacteria. There are a few reasons people become deficient in vitamin D3: • People don't go outside as much • It's difficult to get RDAs from food • As you age you lose the ability to absorb vitamin D3 • The darker your skin, the more vitamin D3 you need • It can be more difficult to get vitamin D3 from the sun depending on where you live • If your liver or gallbladder are damaged, you won't be able to absorb D3 too well • Viruses • A genetic defect If you have TB, you may want to try taking 20,000 IUs of vitamin D3 per day with meals. You may also want to take it with 200mcg of K2 (M-K7 version). This will start helping to build up your immune system and put this microbe back in remission. Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. ABOUT DR. BERG: https://bit.ly/2FwSQQT DR. BERG'S STORY: https://bit.ly/2RwY5GP DR. BERG'S SHOP: https://bit.ly/2RN11yv DR. BERG'S VIDEO BLOG: https://bit.ly/2AZYyHt DR. BERG'S HEALTH COACHING TRAINING: https://bit.ly/2SZlH3o Follow us on FACEBOOK: https://www.messenger.com/t/drericberg TWITTER: https://twitter.com/DrBergDC YOUTUBE: https://www.youtube.com/user/drericberg123 Send a Message to Dr. Berg and his team: https://www.messenger.com/t/drericberg
1-Wajan Ghatane Ka Sahi Tarika | Weight Loss Methods In Hindi | वेट लॉस करने के सही तरी
टीबी डाइट चार्ट || তুবেরকুলোসিস (টিবি ) ডায়েট চার্ট || Tuberculosis/TB Food Diet Chart In Hindi is podcast se aap janege ki #TB ke marij kya khaye #Tuberculosis kya na khayen , Tuberculosis (TB) ke marij ke liye diet plan ke bare me ye sab aap is podcast me janege… Subscribe the channel. It's free- https://www.youtube.com/channe/UC5IcI... Facebook- https://www.facebook.com/XzimerOn/ Twitter- https://twitter.com/xzimer?s=09 --- Send in a voice message: https://anchor.fm/xzimer-medicare/message
Tuberculosis (TB) is a long-standing, urgent threat to global public health, yet it has never been discussed at the highest level of the world stage. That changes this week, as heads of state gather in New York for the UN General Assembly, where they will convene the first-ever UNGA high-level meeting on tuberculosis. After three years of dialogue in advance of this historic event, the meeting will aim to accelerate efforts in ending TB, and it should result in a Political Declaration on TB endorsed by heads of state. On this episode of Take as Directedwe are joined by Dr. Eric Goosby, the current UN Special Envoy on Tuberculosis, to share his hopes and expectations for the meeting, and its potential as an important step towards realizing the WHO global end TB strategy. Hosted by J. Stephen Morrison.
Tuberculosis (TB) is the number one infectious disease killer. Yet, pediatric TB is often overlooked as an urgent public health threat, especially in lower- and middle-income countries. In this episode of Take as Directed, we hear from Dr. Farhana Amanullah, a seasoned clinician and expert in pediatric tuberculosis who runs the largest, private-sector TB program for children in Pakistan at the Indus Hospital Karachi. Dr. Amanullah describes the challenges in diagnosing and treating TB in children and adolescents and shares her expectations for the UN High Level Meeting on Ending TB, which is to take place later this month. Hosted by Sara Allinder.
Tuberculosis is still one of the top ten causes of death worldwide, with 1.4 million people dying from TB in 2015. If your doctor suspects you have the disease it can take up to 6 weeks to get a diagnosis! Tuberculosis (TB) has influenced history. The disease was for centuries associated with poetic and artistic qualities in its sufferers, and was known as "the romantic disease". But in reality there is nothing romantic about the disease. Before drug therapy was available in 1946, nearly half of the people infected with tuberculosis died. Tuberculosis is still one of the top ten causes of death worldwide, with 1.4 million people dying from TB in 2015. If your doctor suspects you have the disease it can take up to 6 weeks to get a diagnosis! In this week’s Oxford Sparks Big Question podcast we visited Dr Philip Fowler, Senior Researcher at University of Oxford Using molecular simulation to predict antibiotic resistance and also runs @bashthebug to ask: Is there a faster way to diagnose Tuberculosis?
November is National Bladder Health Awareness Month. According to the Urology Care Foundation the cost of treating bladder problems in the United States is 70 Billion dollars annually. Nursing home costs due to urinary incontinence are estimated at 6 billion dollars annually. Urinary tract infections create more than 8 million doctor visits every year (5.3 of those 8 million visits are women with infections, 1.3 and 1.2 of those 8 million are children and men respectively). Millions of Americans have neurogenic bladder from a spinal cord injury, multiple sclerosis, Parkinson's disease, stroke, spina bifida, or nerve problems caused by diabetes or major pelvic surgery. More than 1 in 10 military service members injured in Afghanistan and Iraq have urologic trauma injuries, damaging the urinary tract or reproductive organs. For National Bladder Health Awareness Month, we are talking about bladder cancer. Bladder cancer is the 5th most common non-skin cancer in the United States. It is the 4th most common cancer diagnosed in men and by the Veterans Affairs Health System. Nearly 600,000 Americans live with bladder cancer today and 75-80,000 people will be diagnosed in the United States with bladder cancer this year. An estimated 16-17,00 people will die from bladder cancer this year. You are at risk for bladder cancer if you are over 55 years of age and you have one of the following five risk factors: 1. You smoke tobacco, either in the past or currently. 2. you are exposed to chemicals in the workplace used to make plastics, paints, textiles, leather and rubber, 3. you have had prior pelvic radiation, 4. you have chronic urinary tract infections associated with neurologic disease and chronic catheterization 5. you are a patient taking medications linked with increasing bladder cancer risk. In the last episode, we talked about how bladder cancer grows as a papillary tumor within the bladder. It begins on the surface of the bladder, in the lining cells of the bladder called transitional cells. Most bladder cancers then grow into the bladder on a stalk. As tumors grow they can grow roots and invade into the deeper layers of the bladder. As tumors invade the deeper layers of the bladder the stage increases and the chance that the cancer metastasizes or spreads to organs beyond the bladder also increases. Superficial tumors can be resected from the surface of the bladder as their only treatment. Recurrence rates for bladder cancer are at least 50% after initial diagnosis. Careful, scheduled followup cystoscopy in the office on a routine basis is required to check for recurrent tumors. Higher stage tumors that are invading into the bladder muscle or beyond often will need to be treated with other treatments such as chemotherapy, radiation or even removal of the bladder. A bladder cancer can also grow in another way that we did not touch on during the last episode, the tumor can also grow up along the surface of the bladder. When the cancer behaves in this way it does not create a papillary lesion but rather takes up a large surface area of the bladder or is even present in several patches within the bladder. That type of growth is called carcinoma in situ (CIS). I want to illustrate this with an analogy. Picture an empty room stripped of all furniture and decoration. Pretend that is the inside of the bladder. Take a lamp and place it in the middle of the floor. That's a papillary tumor. Now let's carpet the floor. That's carcinoma in situ. In the case of bladder cancer growing as carcinoma in situ it is nearly impossible to resect or cut away all of the tumor both because of the large surface area of the bladder that may be involved. Microscopic changes may also be found within other parts of the bladder that cannot be seen by the cystoscope that will become carcinoma in situ. To treat carcinoma in situ we then need to treat the entire surface of the bladder. We are fortunate that the bladder is a hollow cavity. We can simply place the treatment in a fluid within the bladder itself and it will naturally get to the entire bladder surface if we can hold the treatment in the bladder for a time. There are currently two forms of treatment that can be instilled into the bladder, chemotherapy and immunotherapy. Our most effective and most common treatment is called BCG, Bacillus Calmette-Guerin. (BCG). It is a form of immunotherapy, stimulating the body's natural immune response to recognize and kill cancer cells. Immunotherapy uses the body's natural defense cells to fight a cancer. Cancer grows hiding in plain sight from the body's immune system. Cancer cells are abnormal cells but the body does not kill the cancer in the same way that it tries to kill a bacterium or a virus. A cancer cell is derived from the body's normal cells within an organ. Bladder cancer cells, as are all cancer cells, created when normal cells get faulty DNA instructions and grow aggressively, without organization, and without stopping. The cancer cell is allowed to grow because the body does not see it as foreign because it comes from the body's cells in the first place. If we can make a body recognize a cancer cell as foreign, then the body has incredible tools in the immune system to kill a cancer on its own. That is the essence of immunotherapy. There is currently a lot of research being done using immunotherapy to treat all kinds of cancer including bladder, kidney, colon, skin, lung and others. To date nothing has surpassed BCG. The odd and interesting thing about BCG and putting it into the bladder is that it BCG was originally developed and is still used as a vaccine for tuberculosis. How urologists began to use BCG in the bladder is a bit of a convoluted tale that I will tell at the end of this episode. BCG is used in several circumstances. It is employed: (1) to treat carcinoma in situ or occasionally residual papillary tumors; (2) to reduce the number and frequency of recurrent high grade superficial tumors; and (3) to prevent disease progression (although this remains a controversial point, on which there is no consensus view). BCG treatment is usually started a few weeks after an initial resection and biopsy of the bladder tumor to allow the bladder time to heal. The usual treatment is given once a week for 6 weeks. In the office patients are given live attenuated BCG mixed in 50 ml of normal saline instilled into the bladder via a urethral catheter. Before instillation urinary tract infection is excluded and the catheter is introduced in an atraumatic way. The patient retains the fluid within the bladder for an hour or two. This is to ensure that all the bladder mucosa comes into contact with the BCG. There is a small risk of infection with BCG, therefore the staff administering the BCG are suitably protected with masks, goggles, gloves, and gowns. Patients are advised to bleach their toilets after urinating, so as to neutralize and kill any BCG from the urine. BCG works about 50-60% of the time after its first treatment. The initial 6-week treatment can be repeated if needed, providing an additional 20-30% benefit. Sometimes longer treatment regimens are used. An immune booster called interferon can be added. Long-term maintenance BCG therapy where short courses of three weeks given every few months is also used to try to prevent recurrent bladder cancer. Patients not responding to BCG need to have alternative treatments and have a high risk of disease progression and metastatic disease. Treatment with BCG can cause symptoms and side effect that feel like having the flu, such as fever, chills, and fatigue. It can also cause a burning feeling in the bladder that may increase through the course of a treatment. Rarely, BCG can spread through the body, leading to a systemic infection. How does BCG work? The exact mechanism of action of BCG is not completely understood. It is known that an intact immune system is important for the antitumor activities of BCG. The body's immune system cells are attracted to the bladder and activated by BCG, which in turn affects the bladder cancer cells. But how the body suddenly recognizes and kills a bladder cancer that it did not previously recognize is not well understood. Now let's take a bit of a diversion. BCG is a tuberculosis vaccine. Let's talk about tuberculosis. We don't hear about tuberculosis much in the United States. There are between 9-10,000 cases of tuberculosis reported in the United States annually, with HIV-positive immunocompromised patients being the most susceptible. But tuberculosis recently has made the front page of our local newspapers here in Minnesota because of a small outbreak of difficult to treat tuberculosis within our community. According to the World Health Organizations, Tuberculosis (TB) is one of the top 10 causes of death worldwide. In 2016, 10.4 million people fell ill with tuberculosis, and 1.7 million died from the disease (including 0.4 million among people with HIV). Over 95% of tuberculosis deaths occur in low- and middle-income countries. Seven countries account for 64% of the total, with India leading the count, followed by Indonesia, China, Philippines, Pakistan, Nigeria, and south Africa. in 2016, an estimated 1 million children became ill with tuberculosis and 250 000 children died of tuberculosis (including children with HIV associated tuberculosis). Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. tuberculosis is spread from person to person through the air. When people with lung tuberculosis cough, sneeze or spit, they propel the tuberculosis germs into the air. A person needs to inhale only a few of these germs to become infected. About one-quarter of the world's population has latent tuberculosis, which means people have been infected by tuberculosis bacteria but are not (yet) ill with the disease and cannot transmit the disease. People infected with tuberculosis bacteria have a 5–15% lifetime risk of falling ill with tuberculosis. Worse yet, strains of tuberculosis that are resistant to the most common therapy are becoming more common. The World Health Organization estimates that there were 600, 000 new cases last year with resistance to rifampicin – the most effective first-line drug, of which 490 000 had Multiple drug resistant-tuberculosis. The cost or treating drug resistant tuberculosis is very high, as much as $134,000 per patient. By comparison, first-line therapy requires at least six months of drugs at a cost of $17,000. Here is where our story begins to take on a local note. According to a recent article in the MPLS paper the Star Tribune at least 17 people have been diagnosed within our community recently with active drug resistant Tuberculosis. Health officials are scrambling to identify those closest to those diagnosed to see if those people have either active or latent infections. Testing on 125 people has already turned up 58 cases of latent tuberculosis infection, meaning they carry the disease, and may go on to develop symptoms and become infectious, especially if they have chronic health conditions or as they age and their immune systems weaken. Like those who show symptoms, those with latent infections are being urged to take the second-tier antibiotics for up to 18 to 24 months. Another 150 potential contacts known to investigators of our local outbreak had incomplete date of birth or address information, complicating the efforts to track them down. That means there are potential latent infections in our community left untreated. This is especially chilling as we enter the cough and cold season here in Minnesota. On a positive note, The World Health Organization believes Tuberculosis is curable and preventable. Globally, tuberculosis incidence is falling at about 2% per year. An estimated 53 million lives were saved through tuberculosis diagnosis and treatment between 2000 and 2016. Ending the tuberculosis epidemic by 2030 is among the health targets of the Sustainable Development Goals for the world Health Organization. One goal of the strategy is to immunize against tuberculosis. The United States does not actively immunize against tuberculosis, but many other countries do. The tuberculosis vaccine used is BCG. It was first given as a vaccine in 1921. Development of the BCG vaccine goes back many years prior to 1921. In 1904, scientists isolated Mycobacterium bovis from a cow with tuberculous mastitis. Bovine tuberculosis was a significant cause of death among cattle in the early 20th century and remains a risk today. Scientists quickly got to work studying bovine TB in the lab. But initially working with bovine TB in the laboratory proved difficult. The mycobacterium culture in the laboratory showed a strong tendency to clump. In order to prevent adhesion, in 1908, working together at the Pasteur Institute Albert Calmette, a physician by training and research bad-ass who, according to Wikipedia, had invented the first anti-venom for snake venom and Camille Guérin, a veterinarian by training added bovine bile to the bovine TB culture medium to prevent clumping. After this culture, the M bovis showed a loss of virulence for animals. With each subsequent culture the bovine TB would show less virulence. In 1920, after a period of 13 years and 231 culture passages through the laboratory the culture was regarded as being avirulent or noninfectious. This special M bovis strain was named Bacillus of Calmette and Guérin (Bacille de Calmette et Guérin, BCG), and a vaccine for tuberculosis was born. BCG was first used in humans in 1921 when it was given to a child in Paris. The baby's mother, who had tuberculosis, had died just after the baby was born, and the baby was due to be brought up by its grandmother who also had tuberculosis. The baby developed into a perfectly normal boy. During the next three years (up to July 1924) a further 317 infants were also vaccinated. The story of BCG then takes a cloudy turn when, in 1930, when 72 vaccinated children developed tuberculosis in Lübeck, Germany, due to a contamination of some batches of the vaccine. Mass vaccination of children was stopped after the disaster but then reinstated in many countries after 1932, when new and safer production techniques were implemented. Strains of BCG are still used today in vaccination programs around the world. BCG vaccine has a documented protective effect against meningitis and disseminated tuberculosis in children. It does not prevent primary infection and, more importantly, does not prevent reactivation of latent pulmonary infection, the principal source of bacillary spread in the community. The impact of BCG vaccination on transmission of Human TB is therefore limited. Next in our tale about how BCG came to be used for bladder cancer comes thanks to Dr. Raymond Pearl, a prolific writer and biologist from Johns Hopkins. Pearl reported in 1929 that among the first autopsy studies at Johns Hopkins there was a negative association of patients with tuberculosis and cancer and he proposed that tuberculosis infection somehow prevents cancer. That assertion is false. Later analysis of his data by others showed that his data had significant selection bias. Criticism of this paper and his analytical methods at the time in particular was to be a stumbling block in his career advancement when Dr. Pearl was being considered for a position at the Bussey Institute at Harvard. The most vociferous critic considered Pearl's work superficial, self-promoting, and a nuisance likening it to “boyish whittling.” But that initial analysis by Pearl sparked interest in the immunobiology of tuberculosis infection as a way to stimulate the immune system to treat cancer. Interest in BCG and tuberculosis as a cancer treatment waxed and waned between 1930 and 1970 but the story continues after intra-lesion injections of BCG for melanoma of the skin proved successful. After the melanoma treatments proved successful for the skin an adventurous urologist injected and successfully treated a melanoma of the bladder through cystoscopic injection, published in the Journal of urology in 1975. This success sparked an interest in BCG treatments of other forms of bladder cancer. In 1976 the first report of BCG treatment for transitional cell carcinoma was published by Dr. A. Morales in the Journal of Urology. This paper is included in a series of papers in an anniversary edition of the Journal of Urology now celebrating its 100th year of publication. You can find it at www.JU100.org. The author was applauded for his “courage as well as his results” by the editorial accompanying the initial publication. It's still not clear if the appropriate animal modeling had been performed prior to clinical experimentation on people, but the successful treatment created the spark that ignited larger research studies that proved the efficacy of BCG and resulted today in many of our patients being treated with BCG. More “academic” studies followed. Dr. Donald Lamm was awarded the initial NIH-funded contract to evaluate BCG immunotherapy of superficial bladder cancer in a randomized clinical trial (1978). This work, accruing an eventual 231 patients, resulted in the first controlled trial demonstrating the efficacy of intra-vesical BCG immunotherapy. Urologists have been using BCG as a treatment for superficial bladder cancer ever since. Let's stop there. I have really taken us on a journey in this episode. I wonder what Drs. Calmette and Guerin would have thought in 1908 as they were adding bile to a bovine TB culture medium if you told them we would eventually use a tuberculosis vaccine they would develop to treat bladder cancer. To get from there to here otherwise cautious urologist had to become the adventurous surgeons and scientists that we have talked about in previous podcasts, the phrase that caught my eye from the editorial introducing the 100th anniversary edition of the Journal of Urology. You can read the article at http://www.ju100.org/. Bibliography/Reference: https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=US&LAN=EN&outtype=html https://www.cancer.org/cancer/bladder-cancer/treating/intravesical-therapy.html http://www.startribune.com/tb-outbreak-has-health-officials-on-alert/455468773/ https://www.researchgate.net/publication/11202692_BCG_use_of_bacille_Calmette-Guerin_in_superficial_bladder_cancer [accessed Nov 11 2017]. https://en.wikipedia.org/wiki/Albert_Calmette https://en.wikipedia.org/wiki/Camille_Guérin
In global health circles, Dr Eric Goosby’s reputation precedes him. A physician by training, he has been a leader in the development and implementation of HIV/AIDS policy for 30 years and is perhaps best known for his role as the US Global AIDS Coordinator (2009-2013). In 2015, Dr Goosby accepted an appointment as the UN Secretary-General’s Special Envoy on Tuberculosis (TB), and it was in this capacity that he visited Canberra in late May 2017, during which Camilla Burkot interviewed him at the Development Policy Centre about Australia's role in the global fight against TB.
Tuberculosis (TB) is a communicable disease with standardized regimens for medical treatment. When drug resistance, persistent disease, or other complications occur, medical resolution of the disease may not be the only feasible option. This webinar will cover the indications for surgery in TB patients.
Tuberculosis (TB) is a communicable disease with standardized regimens for medical treatment. When drug resistance, persistent disease, or other complications occur, medical resolution of the disease may not be the only feasible option. This webinar will cover the indications for surgery in TB patients.
The House Call Doctor's Quick and Dirty Tips for Taking Charge of Your Health
Tuberculosis caused 1.5 million deaths in 2013 alone. Learn the symptoms and treatment of one of the deadliest, most contagious diseases in the world. Visit the website: http://bit.ly/1EuTJxQ
"Challenges to the Elimination of Tuberculosis (TB) in the United States" This talk will review the need to bridge the implementation, knowledge, and ambition gaps to succeed in the elimination of TB here and elsewhere.
March 21, 2010 — Researchers at Albert Einstein College of Medicine of Yeshiva University have found two novel ways of killing the bacteria that cause tuberculosis, a disease responsible for an estimated two million deaths each year. The findings are published in the March 21 online issue of Nature Chemical Biology.
© 2020-2025 Ivy Podcast Discovery LLC
